Last reviewed · How we verify
A Phase II Study Using SGN-15 (cBR96 - Doxorubicin Immunoconjugate) in Combination With Taxotere for the Treatment of Metastatic or Recurrent Breast Carcinoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them without harming normal cells. Combining chemotherapy with monoclonal antibody therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining docetaxel and monoclonal antibody therapy in treating women who have metastatic or recurrent breast cancer.
Details
| Lead sponsor | Seagen Inc. |
|---|---|
| Phase | Phase 2 |
| Status | TERMINATED |
| Start date | 2000-10 |
| Completion | 2003-04 |
Conditions
- Breast Cancer
Interventions
- cBR96-doxorubicin immunoconjugate
- docetaxel
Countries
United States